Page 14 - Truth Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The webcast will be available on demand starting Monday, January 11 th, 2021 at 6:00 AM ET. Replays of the presentation will be available for 90 days following the event. About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatme...

Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas News provided by Share this article Share this article HOUSTON, Dec. 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Annamycin for treatment of soft tissue sarcomas.  Moleculin recently announced that the FDA had allowed it...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. OrthoPediatrics Corp. Announces First PNP|FEMUR Case Performed in the United Kingdom OrthoPediatrics Corp.December 29, 2020 GMT WARSAW, Ind., Dec. 29, 2020 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, today announced the first surgery in the United Kingdom utilizing the new Pediatric Nailing Platform | FEMUR (“PNP|FEMUR”). Representing a significant new option for certain anatomie...

Published: Dec 21, 2020 WARSAW, Ind., Dec. 21, 2020 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its expansion into the U.K. commercial market with the approval and launch of two innovative surgical systems that can provide meaningful advances over existing products. OrthoPediatrics recently received U.K. regulatory clearance for its Pediatric Nailing Platform | FEMUR (“PNP|FEMUR”), which was launched in the U.S. in 2018 as the first...

Houston, TX –  December 17, 2020 – Moleculin Biotech, Inc., (NASDAQ: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) is allowing the company’s Investigational New Drug (IND) application to study Annamycin for the treatment of soft tissue sarcoma lung metastases to go into effect.  This allows Moleculin to begin a Phase 1B/2 clinical trial in the US for patients with soft tissue sarcoma that has metastasized t...